June 29, 2026
CasInvent Pharma
News
June 29, 2026
CzechInvest grant successfully completed — key milestones reached in CK1 inhibitor research
Read more
May 07, 2026
CasInvent was selected for EIC Pre-Accelerator funding — a crucial step in securing progress towards the clinic
Read more
November 14, 2025
CasInvent Participates in Leukemia360 to Advance Collaboration in AML Research
Read more
November 06, 2025
CasInvent at BIO-Europe 2025: Strengthening Global Partnerships
Read more
October 01, 2025
CasInvent Pharma at Prague.bio 2025: A Look Back
Read moreSeptember 29, 2025
CasInvent Reaches Over 25 Million Viewers on World Cancer Research Day 2025
Read moreAugust 25, 2025
Visit from Liberi Group at CasInvent
Read moreAugust 25, 2025
CasInvent Was Supported By CzechInvest’s Technological Incubation Program
Read more
July 02, 2025
CasInvent Pharma Secures Next Investment Round with Strong Support from Existing and Local Investors to Advance CK1 Inhibitor Development for Treatment-Resistant Cancer Patients
Read moreApril 01, 2025
CasInvent Wins the 9th TAČR SIGMA Public Competition!
Read more
December 05, 2024
CasInvent Pharma Receives Top Honor at Transfera Technology Days 2024
Read more
November 03, 2024
CasInvent Pharma Joins Czech Presidential Delegation at the Pharmaceutical and Biotechnological Forum in Switzerland
Read more
September 30, 2024
PANC-CKI Consortium led by CasInvent Pharma Secures €4M Eurostars Grant for Pancreatic Cancer Research
Read moreJuly 17, 2024
Dr. Jean-Pierre Bizzari joining CasInvent as a new Scientific Advisory Board member
Read more
January 31, 2024
CasInvent Pharma raises € 1.6 million in Pre-Series A Financing to Support the Development of CK1 Inhibitors for Treatment-Resistant Solid and Hematological Tumours
Read more
February 15, 2023
SGC recommends the compound MU1742 as a new chemical probe for protein kinases CK1δ and CK1ε, developed in collaboration with the researchers of CasInvent Pharma, a.s.
Read more
September 13, 2022
CasInvent Pharma Raises €1.3 Million from KHAN-I and i&i Biotech Fund to Support the Development of New Casein Kinase 1 Inhibitors for the Treatment of Leukemias and Solid Tumors
Read more
August 29, 2022
CasInvent Pharma appoints Alexander Scheer as Chief Scientific Officer
Read moreApril 25, 2022
Czech National Institute for Drug Control agrees to support CasInvent Pharma during the execution of preclinical program
Read moreOctober 20, 2021
Learn more about CasInvent Pharma, a.s. in Hospodarske Noviny
Read more
October 01, 2021
CasInvent Pharma receives the Neuron Award for excellent Technology Transfer
Read moreJanuary 1, 2021
Learn more about CasInvent Pharma
Read moreDecember 14, 2020